April 25, 2024 — BY Elizabeth Anderson
Biogen Reaps Profits On The Back Of Cost Cuts
Economists attributed this positive performance to the biotechnological company’s cost-cutting drive and an uptake in sales of its newly-launched Alzheimer’s drug, LEQEMBI. Analysts predicted t...
Read more